- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07944547
APL-1702 Photodynamic Therapy in Patients With High-Risk HPV-Positive Cervical Intraepithelial Neoplasia Grade II/III (CIN2/3) (AEGIS)
An Exploratory Clinical Study of APL-1702 (Drug-Device Combination) Photodynamic Therapy in Patients With High-Risk HPV-Positive Cervical Intraepithelial Neoplasia Grade 2 or 3 (CIN2/3)
This investigator-initiated, open-label, exploratory study evaluates the safety and preliminary efficacy of APL-1702 photodynamic therapy in participants with high-risk human papillomavirus (hrHPV)-positive cervical intraepithelial neoplasia grade 2 (CIN2) or grade 3 (CIN3). Part 1 enrolls adults with CIN2 into six treatment-regimen groups to identify a preferred regimen, primarily on the basis of histological regression at Week 24 after the first treatment. Part 2 enrolls adults aged 18 to 45 years with hrHPV-positive CIN3 and evaluates three treatments administered at Day 0, Month 1, and Month 3. Participants are assessed for histological regression, hrHPV clearance, and safety.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Yu Zhang, MD
- 전화번호: 0731-89753999
- 이메일: cszhangyu@126.com
연구 장소
-
-
Hunan
-
Changsha, Hunan, 중국, 410008
- 모병
- Xiangya Hospital of Central South University
-
연락하다:
- Yu Zhang, MD
- 전화번호: 0731-89753999
- 이메일: cszhangyu@126.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Voluntary participation in this study, understanding of the study procedures, and ability to provide written informed consent;
- Part 1 Age ≥18 years; Part 2 Age≥18 years and≤45 years
- CIN histology: Part 1, hrHPV-positive and histologically confirmed CIN2 within 3 months before the first treatment; Part 2, hrHPV-positive and histologically confirmed CIN3 within 3 months before the first treatment, with the lesion involving 50% or less of the cervical area. Histological eligibility is confirmed by the central laboratory.
- Adequate colposcopic examination, with the entire cervical transformation zone and squamocolumnar junction visible and the entire lesion margin visible.
- A strong desire to preserve cervical structure and/or function, and the investigator considers non-surgical treatment acceptable.
- The investigator considers the cervical size suitable for placement of the APL-1702 device
- Negative pregnancy test; no pregnancy planned from study initiation until 3 months after the last treatment or 24 weeks after the first treatment, whichever is later. Participants must have abstained from sexual activity or used effective contraception from the end of the last menstrual period to study entry and must agree to use condoms during the protocol-defined contraceptive period.
Exclusion Criteria:
- Cervical adenocarcinoma in situ (AIS), other glandular epithelial lesions, invasive cervical cancer, or suspected malignant lesions.
- Lesions extending to the vaginal wall, endocervical canal, vaginal fornix, or vulvar region.
- Previous physical or surgical treatment of the cervix resulting in incomplete cervical structure (for example, cold knife conization), or physical or surgical treatment for CIN2 or CIN3 after the current histopathological diagnosis.
- The first study treatment occurs within 7 half-lives after the last dose of an antiviral medication.
- History of toxic shock syndrome.
- Severe pelvic inflammatory disease, severe cervicitis, or other serious gynecological infections identified by colposcopy or clinical examination.
- The investigator considers that vaginal bleeding during treatment may affect treatment efficacy.
- Administration of any inactivated vaccine within 2 weeks before study treatment or any live vaccine within 4 weeks before study treatment.
- Unresolved severe cardiovascular, neurological, psychiatric, endocrine, or hematologic diseases; known severe immunodeficiency; need for long-term glucocorticoids or immunosuppressive therapy; or a history of malignancy within 5 years.
- Clinically significant immunosuppression, confirmed autoimmune disease, or primary immunodeficiency.
- Known or screening-detected active sexually transmitted diseases (STDs), including but not limited to HIV infection, syphilis, or genital herpes, unless adequately treated with negative results before study treatment.
- Presence of a cardiac pacemaker.
- Suspected or known porphyria, or known allergy to the study drug or chemically related compounds.
- Allergy to silicone.
- Pregnant or breastfeeding.
- Childbirth or miscarriage within 6 weeks before enrollment.
- Participation in another clinical trial within 30 days before study treatment.
- Poor compliance or investigator's judgment that the subject is unsuitable for participation.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part 1 - Q3W x 3
Adults with hrHPV-positive CIN2 receive APL-1702 once every 3 weeks for a total of 3 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
|
실험적: Part 1 - Q3W x 6
Adults with hrHPV-positive CIN2 receive APL-1702 once every 3 weeks for a total of 6 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
|
실험적: Part 1 - Q2W x 3
Adults with hrHPV-positive CIN2 receive APL-1702 once every 2 weeks for a total of 3 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
|
실험적: Part 1 - Q2W x 6
Adults with hrHPV-positive CIN2 receive APL-1702 once every 2 weeks for a total of 6 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
|
실험적: Part 1 - Q1W x 3
Adults with hrHPV-positive CIN2 receive APL-1702 once weekly for a total of 3 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
|
실험적: Part 1 - Q1W x 6
Adults with hrHPV-positive CIN2 receive APL-1702 once weekly for a total of 6 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
|
실험적: Part 2 - Month 0/1/3
Adults aged 18 to 45 years with hrHPV-positive CIN3 receive a total of three APL-1702 treatments. |
APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6. APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total). |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1: Histological regression rate at Week 24 after the first treatment
기간: Week 24 after the first treatment
|
Proportion of Part 1 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only, based on central laboratory evaluation of colposcopy-directed cervical biopsy specimens. |
Week 24 after the first treatment
|
|
Part 2: Histological regression rate at Week 24 after the first treatment
기간: Week 24 after the first treatment
|
Proportion of Part 2 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only, based on central laboratory evaluation of colposcopy-directed cervical biopsy specimens. |
Week 24 after the first treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1 hrHPV clearance rate
기간: 28 days after the final treatment course and Week 24 after the first treatment
|
Proportion of Part 1 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment. |
28 days after the final treatment course and Week 24 after the first treatment
|
|
Part 1 incidence and characteristics of adverse events and serious adverse events
기간: From informed consent through Week 96 after the first treatment
|
Type, incidence, severity, duration, outcome, and relationship to the study product of adverse events and serious adverse events. |
From informed consent through Week 96 after the first treatment
|
|
Part 1 long-term hrHPV clearance rate
기간: Weeks 36, 60, and 96 after the first treatment
|
Proportion of Part 1 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment. |
Weeks 36, 60, and 96 after the first treatment
|
|
Part 1 long-term histological regression rate
기간: Weeks 36, 60, and 96 after the first treatment
|
Proportion of Part 1 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only. |
Weeks 36, 60, and 96 after the first treatment
|
|
Part 2 hrHPV clearance rate
기간: Week 24 after the first treatment
|
Proportion of Part 2 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment. |
Week 24 after the first treatment
|
|
Part 2 incidence and characteristics of adverse events and serious adverse events
기간: From informed consent through Week 48 after the first treatment
|
Type, incidence, severity, duration, outcome, and relationship to the study product of adverse events and serious adverse events. |
From informed consent through Week 48 after the first treatment
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- APL1702-IIT-101
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .